Evan Seigerman
Stock Analyst at BMO Capital
(4.07)
# 524
Out of 5,115 analysts
152
Total ratings
55.45%
Success rate
11.54%
Average return
Main Sectors:
Stocks Rated by Evan Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Maintains: Outperform | $35 → $54 | $34.60 | +56.07% | 3 | Dec 9, 2025 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $1,100 → $1,200 | $1,037.15 | +15.70% | 10 | Dec 4, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $120 → $130 | $141.95 | -8.42% | 18 | Aug 8, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $557 → $530 | $469.90 | +12.79% | 16 | Aug 5, 2025 | |
| INCY Incyte | Maintains: Underperform | $52 → $60 | $100.07 | -40.04% | 13 | Jul 30, 2025 | |
| IRON Disc Medicine | Maintains: Outperform | $112 → $120 | $77.32 | +55.20% | 6 | May 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $96 → $115 | $136.06 | -15.48% | 15 | May 6, 2025 | |
| BIIB Biogen | Maintains: Market Perform | $156 → $139 | $179.89 | -22.73% | 27 | Feb 13, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Market Perform | $57 → $61 | $55.05 | +10.81% | 11 | Nov 12, 2024 | |
| GPCR Structure Therapeutics | Initiates: Outperform | $40 | $88.45 | -54.78% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $40 | $7.03 | +468.99% | 1 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $757 → $788 | $741.45 | +6.28% | 17 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $8 → $2.5 | $5.24 | -52.29% | 2 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $263 → $243 | $341.88 | -28.92% | 6 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $5.84 | +105.48% | 2 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $26.44 | +126.93% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $30 | $1.83 | +1,539.34% | 3 | May 12, 2020 |
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $35 → $54
Current: $34.60
Upside: +56.07%
Eli Lilly and Company
Dec 4, 2025
Maintains: Outperform
Price Target: $1,100 → $1,200
Current: $1,037.15
Upside: +15.70%
Gilead Sciences
Aug 8, 2025
Maintains: Outperform
Price Target: $120 → $130
Current: $141.95
Upside: -8.42%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Outperform
Price Target: $557 → $530
Current: $469.90
Upside: +12.79%
Incyte
Jul 30, 2025
Maintains: Underperform
Price Target: $52 → $60
Current: $100.07
Upside: -40.04%
Disc Medicine
May 12, 2025
Maintains: Outperform
Price Target: $112 → $120
Current: $77.32
Upside: +55.20%
Neurocrine Biosciences
May 6, 2025
Maintains: Market Perform
Price Target: $96 → $115
Current: $136.06
Upside: -15.48%
Biogen
Feb 13, 2025
Maintains: Market Perform
Price Target: $156 → $139
Current: $179.89
Upside: -22.73%
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Market Perform
Price Target: $57 → $61
Current: $55.05
Upside: +10.81%
Structure Therapeutics
Feb 28, 2023
Initiates: Outperform
Price Target: $40
Current: $88.45
Upside: -54.78%
Oct 14, 2022
Maintains: Outperform
Price Target: $30 → $40
Current: $7.03
Upside: +468.99%
Aug 4, 2022
Maintains: Outperform
Price Target: $757 → $788
Current: $741.45
Upside: +6.28%
Aug 2, 2022
Downgrades: Market Perform
Price Target: $8 → $2.5
Current: $5.24
Upside: -52.29%
Apr 28, 2022
Maintains: Market Perform
Price Target: $263 → $243
Current: $341.88
Upside: -28.92%
Mar 31, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $5.84
Upside: +105.48%
Nov 19, 2021
Initiates: Outperform
Price Target: $60
Current: $26.44
Upside: +126.93%
May 12, 2020
Maintains: Outperform
Price Target: $13 → $30
Current: $1.83
Upside: +1,539.34%